Research Paper Volume 15, Issue 16 pp 8090—8112
Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
Figure 1. Workflow of this study. The analysis process of HRD-related RNA is shown on the left. HRD scores were obtained by calculating LOH, LST, and TAI for each sample of TCGA-LUAD. Patients were classified as HRD and non-HRD according to cut-off values. The screening and identification of markers are shown to the right. MS4A6A was identified as a potential immunotherapeutic marker by survival analysis, immune microenvironment, and immune checkpoint analysis.